Cost-effectiveness of telbivudine-based optimization and entecavir monotherapy in patients with HBeAg- positive chronic hepatitis B
10.3969/j.issn.1006-5725.2015.07.005
- VernacularTitle:替比夫定优化方案与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的药物经济学评价
- Author:
Xiaoguang YE
;
Renjie OUYANG
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Pharmacoeconomics;
Markov model;
Cost-effectiveness
- From:
The Journal of Practical Medicine
2015;(7):1053-1056,1057
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the cost-effectiveness of telbivudine-based optimization treatment and entecavir monotherapy in patients with HBeAg-positive chronic hepatitis B (CHB). Methods A Markov model for disease progression of CHB was constructed and cost-effectiveness analysis was conducted to estimate their long-term effects and medical costs. Results There were 36.11 expected life years (ELYs) and 23.08 quality adjusted life years (QALYs) gained from treatment with telbivudine optimization, which were longer than 35.95 ELYs and 23.08 QALYs from entecavir treatment. The total cost of telbivudine optimization was 348 863.62 yuan and that of entecavir treatment 349 279.27 yuan. Each extension of a QALYs required for medical expenses of 15 115.41 yuan in telvivudine optimization, which was cheaper than that in entecavir treatment with 15 225.77 yuan. Conclusions Telbivudine-based optimization treatment shows good cost-effectiveness than entecavir monotherapy. Telbivudine-based optimization treatment can be used as the optimum choice for antiviral therapy in CHB.
